These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 14524732)

  • 21. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.
    Bytzer P; Morocutti A; Kennerly P; Ravic M; Miller N;
    Scand J Gastroenterol; 2006 Oct; 41(10):1132-40. PubMed ID: 16990197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of famotidine and omeprazole in healing symptoms of non-erosive gastro-oesophageal reflux disease: randomized-controlled study of gastro-oesophageal reflux disease.
    Wada T; Sasaki M; Kataoka H; Tanida S; Itoh K; Ogasawara N; Oshima T; Togawa S; Kubota E; Yamada T; Mori Y; Fujita F; Ohara H; Nakao H; Sobue S; Joh T; Itoh M
    Aliment Pharmacol Ther; 2005 Jun; 21 Suppl 2():2-9. PubMed ID: 15943840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease.
    Revicki DA; Crawley JA; Zodet MW; Levine DS; Joelsson BO
    Aliment Pharmacol Ther; 1999 Dec; 13(12):1621-30. PubMed ID: 10594397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The concept of complete remission of gastro-oesophageal reflux disease : comparative efficacy of pantoprazole and esomeprazole using the ReQuest questionnaire.
    Thomson AB
    Clin Drug Investig; 2007; 27(10):663-72. PubMed ID: 17803341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is lansoprazole (Prevacid) or omeprazole (Prilosec) more effective in treating erosive esophagitis?
    Kim JD
    J Fam Pract; 2002 Apr; 51(4):384. PubMed ID: 11978268
    [No Abstract]   [Full Text] [Related]  

  • 26. Rabeprazole: an update of its use in acid-related disorders.
    Carswell CI; Goa KL
    Drugs; 2001; 61(15):2327-56. PubMed ID: 11772142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How do we offer clinical relief to patients with gastro-oesophageal reflux disease?
    Galmiche JP
    Eur J Gastroenterol Hepatol; 2000 Jun; 12 Suppl 1():S3-6. PubMed ID: 10929891
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.
    Stolte M; Vieth M; Schmitz JM; Alexandridis T; Seifert E
    Scand J Gastroenterol; 2000 Nov; 35(11):1125-30. PubMed ID: 11145281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The impact of rabeprazole treatment on the quality of life in patients with reflux esophagitis and non-erosive reflux disease].
    Liu XH; Ke MY; Song ZQ; Luo JY; Yuan YZ; Hou XH; Zhu YL; Sun J; Zha H
    Zhonghua Nei Ke Za Zhi; 2005 Nov; 44(11):818-21. PubMed ID: 16316559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pantoprazole: an update of its pharmacological properties and therapeutic use in the management of acid-related disorders.
    Cheer SM; Prakash A; Faulds D; Lamb HM
    Drugs; 2003; 63(1):101-33. PubMed ID: 12487624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain.
    Xia HH; Lai KC; Lam SK; Hu WH; Wong NY; Hui WM; Lau CP; Chen WH; Chan CK; Wong WM; Wong BC
    Aliment Pharmacol Ther; 2003 Feb; 17(3):369-77. PubMed ID: 12562449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice.
    Venables TL; Newland RD; Patel AC; Hole J; Copeman MB; Turbitt ML
    Scand J Gastroenterol; 1997 Jul; 32(7):627-32. PubMed ID: 9246699
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
    Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
    Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic value of potent acid inhibition in gastro-oesophageal reflux disease.
    Monés J
    Drugs; 2005; 65 Suppl 1():35-42. PubMed ID: 16335856
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of proton-pump inhibitor therapy in patients with gastroesophageal reflux disease and difficult-to-control asthma.
    Goh KL; Wong CH
    Expert Opin Pharmacother; 2006 Oct; 7(15):2015-7. PubMed ID: 17020428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group.
    Lundell L; Miettinen P; Myrvold HE; Pedersen SA; Thor K; Lamm M; Blomqvist A; Hatlebakk JG; Janatuinen E; Levander K; Nyström P; Wiklund I
    Eur J Gastroenterol Hepatol; 2000 Aug; 12(8):879-87. PubMed ID: 10958215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients.
    Bytzer P; van Zanten SV; Mattsson H; Wernersson B
    Aliment Pharmacol Ther; 2012 Oct; 36(7):635-43. PubMed ID: 22860764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
    Dickman R; Emmons S; Cui H; Sewell J; Hernández D; Esquivel RF; Fass R
    Aliment Pharmacol Ther; 2005 Sep; 22(6):547-55. PubMed ID: 16167971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Response of unexplained chest pain to proton pump inhibitor treatment in patients with and without objective evidence of gastro-oesophageal reflux disease.
    Kahrilas PJ; Hughes N; Howden CW
    Gut; 2011 Nov; 60(11):1473-8. PubMed ID: 21508423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Helicobacter pylori infection influences symptomatic response to anti-secretory therapy in patients with GORD--crossover comparative study with famotidine and low-dose lansoprazole.
    Adachi K; Hashimoto T; Komazawa Y; Mihara T; Furuta K; Fujishiro H; Ishihara S; Amano Y; Hattori S; Kinoshita Y
    Dig Liver Dis; 2005 Jul; 37(7):485-90. PubMed ID: 15975534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.